Stock Rating for OraSure Technologies, Inc. lowered by Zacks Investment Research

Stock Rating for OraSure Technologies

On Tuesday, Zacks Investment Research downgraded OraSure Technologies, Inc (NASDAQ:$OSUR) from a ‘Buy’ rating to a ‘Hold’ rating.

OraSure Technologies is a diagnostic company who specializes in using patient’s oral fluid to diagnose a range of illnesses from drug use to HIV, They sell to customers including clinical laboratories, public health agencies, workplaces, physicians’ offices, and insurance companies.

During trading on Tuesday OraSure traded at $21.74, trading up 0.60% on its trading volume of 436,293. The company has a 52 week low of $7.09 and a 52 week high of $22.25. They also have 50 and 200-day moving averages of $20.72 and $16.18, respectively. They have a market cap of $1.29 billion. Their beta is currently 1.57, indicating an above average risk of volatility.

Multiple other firms have recently weighed in on the stock:

  • On July 11th, Stephens reiterated an ‘Overweight’ rating with a target price of $19.00.
  • On July 31st, Bidask Club dropped their rating from ‘Buy’ to ‘Hold.
  • Canaccord Genuity, on August 3rd, gave the company a ‘Buy’ rating with a target price increased to $22.00 from the previous price of $21.00.
  • Jefferies Group LLC, in a report on September 12th, reiterated a ‘Buy’ rating with a target price of $20.00.

The company has a consensus target price of $18.04 and an overall rating of ‘Buy’.

The medical supplier reported a $0.09 EPS on August 2nd. That beat the consensus estimates by $0.02. The company outperformed estimates of $36.54 million with a revenue of $40.18 million for the quarter. This was a 28.1% increase in a year-over-year comparison. They had a net margin of 22.29% and a return on equity of 15.64%.

In a transaction on August 31st, insider Brian Smith sold 9,112 shares at an average price of $20.47 for a total of $186,522.64. He currently owns $664,804.19 worth of stock, approximately 32,477. On June 27th, CEO Douglas A. Michels sold 290,495 shares at an average price of $16.75 and a total value of $4,865,791.25. He currently owns 894,012 shares valued at roughly $14, 974,701. Insiders have sold 960,173 shares worth $18,752,210 in the last three months. Insider ownership currently accounts for 6.40%.

Institutional investors have also traded stocks recently;

  • BNP Paribas Arbitrage SA bought 9,723 shares during the period, resulting in a total of 10,718 shares valued at $139,000, constituting a 977.2% increase.
  • Victory Capital Management Inc. bought shares totaling $100,000 during the 1st quarter.
  • Profund Advisors LLC bought an interest in the company with a 1st quarter purchase of $137,000 worth of stock.
  • Pinebridge Investments L.P. bought into the company with an opening investment of $131,000 in the 2nd quarter.
  • First Mercantile Trust Co. bought into the company with an opening investment of roughly $104,000 worth of stock in the 2nd quarter.

Institutional ownership accounts for 92.10% ownership in the company.

Featured Image: mcall

If You Liked This Article Click To Share